Retinal toxicity during pegylated α-interferon therapy for chronic hepatitis C: A multifocal electroretinogram investigation

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 6, 2005, Pages 723-732

  Chisholm, J A ^a   Williams, G ^a   Spence, E ^a   Parks, S ^a   Keating, D ^a   Gavin, M ^a   Mills, P R ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL ACTIVITY; ANUS FISTULA; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ELECTRORETINOGRAM; EXPERIENCE; EYE TOXICITY; FEMALE; HEART PALPITATION; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; IMPOTENCE; MALE; MONITORING; MOOD DISORDER; NEUTROPENIA; OPHTHALMOSCOPY; PANIC; PRIORITY JOURNAL; PSORIASIS; QUANTITATIVE ANALYSIS; RASH; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINOPATHY; SIDE EFFECT;

ADULT; ANTIVIRAL AGENTS; DELAYED-ACTION PREPARATIONS; ELECTRORETINOGRAPHY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; ISCHEMIA; MALE; MIDDLE AGED; PHOTIC STIMULATION; POLYETHYLENE GLYCOLS; REACTION TIME; RETINAL HEMORRHAGE; RETINAL VESSELS; RETROSPECTIVE STUDIES; RIBAVIRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 16344382588     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02365.x     Document Type: Article

References (46)

1. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
2. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 350-6.
3. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91: 309-13.
4. Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alpha. Br J Ophthalmol 1995; 79: 150-2.
5. Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85: 1171-3.
6. Saito H, Ebinuma H, Nagata H, et al. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver 2001; 21: 192-7.
7. Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alpha-2b therapy. Am J Ophthalmol 2001; 131: 782-7.
8. Chambers RB, Downie A, Foote B, et al. Interferon alpha-associated retinopathy. J Am Osteopathol Assoc 1997; 97: 43-5.
9. Kadayifcilar S, Kart H, Gursoy M, et al. Ocular complication with high-dose interferon alpha in chronic active hepatitis. Eye 1999; 13: 241-6.
10. Tokai R, Ikeda T, Miyaura T, et al. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol 2001; 119: 1077-9.
11. Hayasaka S, Nagaki Y, Matsumoto M, et al. Interferon-associated retinopathy. Br J Ophthalmol 1998; 82: 323-5.
12. Schulman JA, Liang C, Kooragayala LM, et al. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003; 110: 437-42.
13. Tu KL, Bowyer J, Schofield K, et al. Severe interferon associated retinopathy. Br J Ophthalmol 2003; 87: 247-8.
14. Savant V, Callow T. Interferon-associated retinopathy. Eye 2002; 17: 534-6.
15. Rubio JE Jr, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina 2003; 23: 546-8.
16. Norcia F, Di Maria A, Prandini F, et al. Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 1999; 213: 339-40.
17. Sugano S, Suzuki T, Watanabe T, et al. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998; 93: 2441-4.
18. Brouty-Boye D, Zetter B. Inhibition of cell motility by interferon. Science 1980; 108: 516-8.
19. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma interferon. J Cell Biol 1987; 104: 689-96.
20. Sidky Y, Borden E. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155-61.
21. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993; 100: 9-14.
22. Purvin VA. Anterior ischaemic optic neuropathy secondary to interferon alpha. Arch Ophthalmol 1995; 133: 1041-4.
23. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
24. Kuchenbecker J, Pump-Schmidt C, Olbright S, et al. Electrophysiological examination of breast cancer patients with tamoxifen retinopathy. Ophthalmologe 2001; 98: 81-5.
25. Lazzaroni F, Scorolli L, Pizzoleo CF, et al. Tamoxifen retinopathy: does it really exist? Graefes Arch Clin Exp Ophthalmol 1998; 236: 669-73.
26. Jiang C, Hansen RM, Gee BE, et al. Rod and rod mediated function in patients with beta-thalassemia major. Doc Ophthalmol 1998-99; 96: 333-45.
27. Vobig MA, Klotz T, Staak M, et al. Retinal side-effects of sildenafil. Lancet 1999; 353: 375.
28. Sandberg MA, Rose JB, Bernson EL. Cone and rod function in vitamin A deficiency with chronic alcoholism and in retinitis pigmentosa. Am J Ophthalmol 1977; 84: 658-65.
29. Scholl HPN, Zrenner E. Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 2000; 45: 29-47.
30. Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequency complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27: 1421-7.
31. McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003; 61: 1690-4.
32. Ponjavic V, Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 2001; 102: 63-72.
33. Harding GF, Wild JM, Robertson KA, et al. Electrooculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000; 41: 1420-31.
34. Penrose PJ, Tzekov RT, Sutler EE, et al. Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina 2003; 23: 503-12.
35. Marmor MF, Hood DC, Keating D, et al. Guidelines for basic multifocal electroretinography. Doc Ophthalmol 2003; 106: 105-15.
36. Sutler EE, Tran D. The field topography of ERG components in man: I. The photopic luminance response. Vis Res 1992; 32: 433-46.
37. Suller EE. Imaging visual function with the multifocal m-sequence technique. Vis Res 2001; 41: 1241-55.
38. Brown GC. Retinal arterial obstructive disease. In: Schachat, AP. Murphy, RB. Ryan, SJ. eds. Retina, Vol. 2, Medical Retina. St Louis, Missouri, USA: Mosby-Year Book, 1994: 1361-77.
39. Brown GC, Brown MM, Hiller T, et al. Cotton wool spots. Retina 1985; 5: 206-14.
40. Hood DC. Assessing retinal function with the multifocal technique. Prog Ret Eye Res 2000; 19: 607-46.
41. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
42. Zegans ME, Anninger W, Chapman C, et al. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2001; 13: 423-7.
43. Keeling PW, O'Day J, Ruse W, et al. Zinc deficiency and photoreceptor dysfunction in chronic liver disease. Clin Sci (Lond) 1982; 62: 109-11.
44. Parks SW, Sandinha T, Purdie A, et al. Do rods have a significant influence on the photopic multifocal ERG response? An interesting case. Invest Ophthalmol Vis Sci 2004; 45: S4235.
45. Forton DM, Thomas HC, Murphy C, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-9.
46. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10: 81-6.